Health-related Quality of Life Assessment Using St. George's Respiratory Questionnaire in Asthmatics on Inhaled Corticosteroids

Overview

Journal Lung India

Specialty Pulmonary Medicine

Date 2012 Feb 21

PMID 22345912

Authors

Thomas Sabin

Gurumurthy Parthasarathi

Mahesh A Padukudru

Affiliations

Soon will be listed here.

Abstract

Context: Chronic diseases like asthma have significant effects on patients' health-related quality of life (HRQoL). HRQoL measures additional indices as compared to objective measurements like spirometry.

Aims: To assess and compare disease-specific quality of life in asthma patients using St. George's Respiratory Questionnaire (SGRQ) receiving fluticasone, beclomethasone, and budesonide (BUD).

Settings And Design: A prospective, open label, randomized, parallel group study conducted at a tertiary care teaching hospital in South India.

Materials And Methods: A 6-month follow-up of 277 patients with mild, moderate, and severe persistent asthma was randomized to receive fluticasone propionate (FP), BUD, or beclomethasone dipropionate (BDP) in equipotent doses according to their global initiative on asthma (GINA) severity.

Statistical Analysis Used: Data analyzed using SPSS version: 13.0. General linear-repeated measures using the post-hoc bonferroni method assessed significance between treatment groups.

Results: Significant decrease (P < 0.05) in each SGRQ domains and total scores as well as improvement in FEV(1) (P < 0.05) was observed in all study subjects. A significant early response (P < 0.05) was noted after 15 days treatment in patients receiving FP with respect to SGRQ (activity, impact and total) scores and dyspnea indices, but not FEV(1). This improvement with FP was due to its greater effect in patients with moderate and severe persistent asthma. No difference was noted subsequently in all outcome measures studied until 6 months.

Conclusions: There was evidence for an early QoL improvement to FP as compared to BUD or BDP in moderate and severe persistent asthma. Subsequently, the three ICS showed similar improvements in lung functions and dyspnea indices throughout the study.

References

Hawthorne G, Richardson J, Osborne R . The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. Qual Life Res. 1999; 8(3):209-24. DOI: 10.1023/a:1008815005736. View

Adams N, Bestall J, Lasserson T, Jones P . Inhaled fluticasone versus inhaled beclomethasone or inhaled budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev. 2005; (2):CD002310. DOI: 10.1002/14651858.CD002310.pub3. View

Ige O, Sogaolu O . The clinical efficacy of fluticasone propionate (Fluvent) compared with beclomethasone dipropionates (Becotide) in patients with mild to moderate brochial asthma at the University College Hospital, Ibadan, Nigeria. West Afr J Med. 2003; 21(4):297-301. DOI: 10.4314/wajm.v21i4.28003. View

Meszaros A, Zelko R, Mesko A, Vincze Z . Factorial design for the analysis of patient's quality of life in asthma. Qual Life Res. 2005; 14(1):191-5. DOI: 10.1007/s11136-004-3927-4. View

Fabbri L, Burge P, Croonenborgh L, Warlies F, Weeke B, Ciaccia A . Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group. Thorax. 1993; 48(8):817-23. PMC: 464708. DOI: 10.1136/thx.48.8.817. View

Meek P, Lareau S . Critical outcomes in pulmonary rehabilitation: assessment and evaluation of dyspnea and fatigue. J Rehabil Res Dev. 2004; 40(5 Suppl 2):13-24. DOI: 10.1682/jrrd.2003.10.0013. View

Casaburi R, Mahler D, Jones P, Wanner A, San P, ZuWallack R . A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002; 19(2):217-24. DOI: 10.1183/09031936.02.00269802. View

Davies B . A comparison of beclomethasone dipropionate and budesonide in the treatment of asthma. Br J Clin Pract. 1993; 47(2):87-93. View

Molimard M, Martinat Y, Rogeaux Y, Moyse D, Pello J, Giraud V . Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide. Respir Med. 2005; 99(6):770-8. DOI: 10.1016/j.rmed.2004.10.024. View

10.

Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M . Comparison of the responsiveness of different disease-specific health status measures in patients with asthma. Chest. 2002; 122(4):1228-33. DOI: 10.1378/chest.122.4.1228. View

11.

Johnson M . Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998; 101(4 Pt 2):S434-9. DOI: 10.1016/s0091-6749(98)70155-1. View

12.

Adams N, Lasserson T, Cates C, Jones P . Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev. 2007; (4):CD002310. PMC: 8447218. DOI: 10.1002/14651858.CD002310.pub4. View

13.

Donohue J, van Noord J, Bateman E, Langley S, Lee A, Witek Jr T . A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002; 122(1):47-55. DOI: 10.1378/chest.122.1.47. View

14.

Mahler D, Weinberg D, Wells C, Feinstein A . The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest. 1984; 85(6):751-8. DOI: 10.1378/chest.85.6.751. View

15.

Berend N, Kellett B, Kent N, Sly P . Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate. Respirology. 2001; 6(3):237-46. DOI: 10.1046/j.1440-1843.2001.00329.x. View

16.

Sanjuas C, Alonso J, Prieto L, Ferrer M, Broquetas J, Anto J . Health-related quality of life in asthma: a comparison between the St George's Respiratory Questionnaire and the Asthma Quality of Life Questionnaire. Qual Life Res. 2002; 11(8):729-38. DOI: 10.1023/a:1020897816228. View

17.

Jones P, Quirk F, Baveystock C, Littlejohns P . A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis. 1992; 145(6):1321-7. DOI: 10.1164/ajrccm/145.6.1321. View

18.

. Dyspnea. Mechanisms, assessment, and management: a consensus statement. American Thoracic Society. Am J Respir Crit Care Med. 1999; 159(1):321-40. DOI: 10.1164/ajrccm.159.1.ats898. View

19.

Miller M, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R . General considerations for lung function testing. Eur Respir J. 2005; 26(1):153-61. DOI: 10.1183/09031936.05.00034505. View